Non-Small Cell Lung Cancer Clinical Trial Opportunity

You may qualify for a clinical trial at New York University if:

- You have undergone surgery for Stage IB, II or IIIA Non-Small Cell Lung Cancer
- Surgery was performed less than 12 weeks ago or chemotherapy was completed no more than 6 weeks ago

Study:

- Title: Double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recombinant MAGE-A3 + AS15 as adjuvant therapy in patients with resected NSCLC.
- International, multi-center trial enrolling 2270 patients
- Vaccine consists of MAGE-A3 protein plus three immunostimulants
- Vaccine is given intramuscularly thirteen times over 28 months at outpatient visit.

For information, please contact

- Amy Metula, RN, NP at (212) 731-5665 or
- Audrey Sorensen, RN at (212) 263-2562

NYUSOM
IRB APPROVED
03/17/2008